Navigation Links
STAAR Surgical Receives Approval to Market Visian(R) Toric Implantable Collamer Lens in China



MONROVIA, Calif., Feb. 29 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced it has received approval from the State Food and Drug Administration of the People's Republic of China (SFDA) to market the STAAR Visian(TM) Toric Implantable Collamer Lens to ophthalmologists and other eye care professionals in the country for the treatment of nearsightedness and astigmatism. In addition the SFDA granted approval to STAAR to market the STAAR Visian ICH, an implantable collamer lens to correct hyperopia or farsightedness.

"This approval has significant strategic importance for STAAR and positions us for continued growth in China," said Barry G. Caldwell, President and CEO of STAAR Surgical. "The approval of both the Visian Toric ICL and the Visian Hyperopic ICL represents a solid endorsement of the STAAR technology. The Visian Myopic ICL was approved in China during July 2006 and has enjoyed significant growth. With these additional approvals, we are positioned to expand our presence in a market where the demographics are very favorable."

According to Market Scope, a leading source for ophthalmic market data, there are over 500 million myopes and nearly 50 million hyperopes in China making it the largest potential refractive market in the world. In South Korea, where the population is believed to have a mean myopia rate similar to that of China, phakic implant procedures are estimated to have reached seven percent of the LASIK market. According to data presented at an ophthalmic meeting in Japan during January, STAAR's Visian ICL and TICL were used in approximately 60% of those procedures. "Our goal in China over time is to at least replicate the market penetration we are achieving in South Korea," Mr. Caldwell added.

Made of STAAR's proprietary, highly biocompatible Collamer(R) material, the ICL, TICL and the ICH are the only minimally invasive foldable lenses of their kind approved for the Chinese commercial market. As a result of the unique foldable design, the ICL procedure allows an incision up to 50% smaller than competing technology, and its placement in the eye behind the iris provides a more aesthetically pleasing outcome. These approvals in China are for treatments of myopic patients with refractive errors between -3.00 and -20.0 and astigmatism up to six diopters. The hyperopic approval is for patients with refractive errors between +1.0 to +4.0.

About STAAR Surgical

STAAR is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 40 countries. More information is available at

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including any statements of the plans, strategies, and objectives of management for future operations, any statements regarding expectations for success of the ICL, TICL or other products in China, the U.S. or other markets, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include our limited capital resources and limited access to financing, the challenge of managing foreign subsidiaries, the willingness of surgeons and patients to adopt a new product and procedure and other factors beyond our control, including those detailed from time to time in our reports filed with the Securities and Exchange Commission. STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so.

CONTACT: Investors Media

EVC Group EVC Group

Douglas Sherk, 415-896-6820 Steve DiMattia, 646-277-8706

Matthew Selinger, 415-896-6817

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
2. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
3. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
4. National Surgical Hospitals Acquires Majority Share of Houston-Area Surgery Center
5. Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011
6. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
7. Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic
8. Sunnylife Global Announces Completion of Surgical Wing of Xiang Tan World Friendship Hospital
9. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software ... events in five states to develop and pitch their BIG ideas to improve health ... state are competing for votes to win the title of SAP's Teen Innovator, an ...
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced ... 29, 2015 at 11:00 a.m. Israel time, at ... 98 Yigal Allon Street, 36 th Floor, Tel Aviv, ... Eric Paneth and Izhak Tamir to the Board of ... as external directors; , approval of an amendment to certain terms ...
(Date:11/24/2015)... Nov. 24, 2015  Twist Bioscience, a company ... Leproust, Ph.D., Twist Bioscience chief executive officer, will ... on December 1, 2015 at 3:10 p.m. Eastern ... City. --> --> ... Twist Bioscience is on Twitter. Sign up to ...
Breaking Biology Technology:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
Breaking Biology News(10 mins):